Clinical Trial

Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)

Study acronym: Hi-DoRi-3
Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated July 24, 2020 (before its estimated August 2025 completion). Its status may not reflect the trial's current state.
Summary
The purpose of this study is to investigate the effectiveness and safety of the regimen including high dose rifampicin for individualized duration (3 months after Culture Conversion) for the treatment of drug-sensitive pulmonary tuberculosis.
Trial Details
NCT Number NCT04485156
Lead Sponsor Seoul National University Hospital
Collaborators: Chonnam National University Hospital, National Medical Center, Seoul, Pusan National University Hospital, Pusan National University Yangsan Hospital, Seoul National University Bundang Hospital, SMG-SNU Boramae Medical Center, Severance Hospital, Korean Institute of Tuberculosis, International Tuberculosis Research Center, Korean Center for Disease Control and Prevention
Conditions Tuberculosis, Pulmonary
Enrollment 926 participants
Start Date 2020-09
Primary Completion 2025-08 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2020-07-24